Key result
BACON therapy in patients with inoperable squamous lung cancer yielded >50% tumor regression in 45% of extensive and 33% of limited disease cases, improving survival over historical controls.
Why the study?
Does the BACON regimen improve tumor regression and survival in patients with inoperable squamous lung cancer?
Cohort (n=50)
Does the BACON regimen improve tumor regression and survival in patients with inoperable squamous lung cancer?
The BACON regimen demonstrated tumor regression and improved survival compared to historical controls in patients with inoperable squamous lung cancer.
Answers are grounded in this paper and cite their sources.
May warrant prospective evaluation of BACON; leaves open efficacy questions given case-report design and historical controls.
Fifty patients with inoperable squamous carcinoma of the lung. 38 with extensive, and 12 with limited disease, were treated with BACON. Tumor regression greater than 50% was observed in 17 patients (45%) with extensive, and four patients (33%) with limited disease. Stabilization of disease for greater than or equal to 8 weeks was seen in four extensive and eight limited patients, and had the same prognostic importance with regard to survival as response: in extensive disease, responding and stable patients had median survival (MST) of 26 weeks from start of therapy, while MST for non-responders was 9 weeks. MST in limited disease (all patients responding or stable) was 32 weeks. Analysis of survival in extensive disease by performance status showed improvement in each category over historical control results for supportive care alone. BACON was better tolerated and probably more effective when CCNU was given every 8 weeks, rather than every 4 weeks.
No takes yet. Share an insight, caveat, or question.
Livingston et al. (1976) conducted a cohort in inoperable squamous carcinoma of the lung (n=50). BACON (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) vs. Historical controls (supportive care alone) was evaluated on Tumor regression >50%. BACON therapy in patients with inoperable squamous lung cancer yielded >50% tumor regression in 45% of extensive and 33% of limited disease cases, improving survival over historical controls.
Synapse has enriched 10 related papers. Consider them for comparative context: